Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World
Data from the Czech Republic and Slovakia

J 2019

Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia

KRÁL, Zdeněk; Jozef MICHALKA; Heidi MOCIKOVA; Jana MARKOVA; Alice SYKOROVA et al.

Základní údaje

Originální název

Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia

Autoři

Vydání

Journal of Cancer, Australia, IVYSPRING INT PUBL, 2019, 1837-9664

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Austrálie

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.565

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/19:00111949

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.7150/jca.29308

UT WoS

000484111400004

EID Scopus

2-s2.0-85072538201

Klíčová slova anglicky

antibody-drug conjugate; CD30; brentuximab vedotin; Hodgkin lymphoma; registries; stem cell transplantation

Štítky

14110212, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 5. 2020 10:38, Mgr. Tereza Miškechová

Anotace

V originále

Introduction: Clinical trials have demonstrated the effectiveness of the CD30-targeted antibody- drug conjugate brentuximab vedotin (BV) for the treatment of relapsed/refractory Hodgkin lymphoma (R/R HL). In this study, we report on outcomes with BV in a real-world setting using data collected in clinics in the Czech Republic and Slovakia. Patients and Methods: Clinical and epidemiological data for patients with R/R HL who received treatment with BV at eight centers across the Czech Republic and Slovakia were examined. Data were amalgamated and analyzed retrospectively. Results: Clinical data for 58 patients (median age: 30.5 years) with R/R HL who received BV during the course of their treatment were collected and analyzed. Patients had received a median of 3 prior treatment regimens and most (91%) were treated with BV after relapse following autologous stem cell transplantation. Therapeutic responses after BV included 19 (33%) complete responses (CRs) and 8 (14%) partial responses. CRs occurred more frequently in patients who had received fewer prior treatment regimens. The 1-, 2-, and 3-year overall survival (OS) rates from initiation of BV were 78%, 62%, and 41%, respectively. Conclusion: Response rates and OS in this analysis of BV in real-world settings in the Czech Republic and Slovakia were consistent with those reported for pivotal clinical trials and from previous studies outside the clinical trial setting. The results support the efficacy of BV for treatment of R/R HL in real-life clinical practice.

Citovat

KRÁL, Zdeněk; Jozef MICHALKA; Heidi MOCIKOVA; Jana MARKOVA; Alice SYKOROVA; David BELADA; Alexandra JUNGOVA; Samuel VOKURKA; Marie LUKASOVA; Vit PROCHAZKA; Juraj DURAS; Roman HAJEK; Ladislav DUŠEK; L'ubos DRGONA; Miriam LADICKA; Veronika BALLOVA a Andrei VRANOVSKY. Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia. Journal of Cancer. Australia: IVYSPRING INT PUBL, 2019, roč. 10, č. 21, s. 5041-5048. ISSN 1837-9664. Dostupné z: https://doi.org/10.7150/jca.29308.

@article{1597497,
   author = {Král, Zdeněk and Michalka, Jozef and Mocikova, Heidi and Markova, Jana and Sykorova, Alice and Belada, David and Jungova, Alexandra and Vokurka, Samuel and Lukasova, Marie and Prochazka, Vit and Duras, Juraj and Hajek, Roman and Dušek, Ladislav and Drgona, L'ubos and Ladicka, Miriam and Ballova, Veronika and Vranovsky, Andrei},
   article_location = {Australia},
   article_number = {21},
   doi = {https://doi.org/10.7150/jca.29308},
   keywords = {antibody-drug conjugate; CD30; brentuximab vedotin; Hodgkin lymphoma; registries; stem cell transplantation},
   language = {eng},
   issn = {1837-9664},
   journal = {Journal of Cancer},
   title = {Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia},
   url = {http://dx.doi.org/10.7150/jca.29308},
   volume = {10},
   year = {2019}
}

TY  - JOUR
ID  - 1597497
AU  - Král, Zdeněk - Michalka, Jozef - Mocikova, Heidi - Markova, Jana - Sykorova, Alice - Belada, David - Jungova, Alexandra - Vokurka, Samuel - Lukasova, Marie - Prochazka, Vit - Duras, Juraj - Hajek, Roman - Dušek, Ladislav - Drgona, L'ubos - Ladicka, Miriam - Ballova, Veronika - Vranovsky, Andrei
PY  - 2019
TI  - Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia
JF  - Journal of Cancer
VL  - 10
IS  - 21
SP  - 5041-5048
EP  - 5041-5048
PB  - IVYSPRING INT PUBL
SN  - 18379664
KW  - antibody-drug conjugate
KW  - CD30
KW  - brentuximab vedotin
KW  - Hodgkin lymphoma
KW  - registries
KW  - stem cell transplantation
UR  - http://dx.doi.org/10.7150/jca.29308
L2  - http://dx.doi.org/10.7150/jca.29308
N2  - Introduction: Clinical trials have demonstrated the effectiveness of the CD30-targeted antibody- drug conjugate brentuximab vedotin (BV) for the treatment of relapsed/refractory Hodgkin lymphoma (R/R HL). In this study, we report on outcomes with BV in a real-world setting using data collected in clinics in the Czech Republic and Slovakia. Patients and Methods: Clinical and epidemiological data for patients with R/R HL who received treatment with BV at eight centers across the Czech Republic and Slovakia were examined. Data were amalgamated and analyzed retrospectively. Results: Clinical data for 58 patients (median age: 30.5 years) with R/R HL who received BV during the course of their treatment were collected and analyzed. Patients had received a median of 3 prior treatment regimens and most (91%) were treated with BV after relapse following autologous stem cell transplantation. Therapeutic responses after BV included 19 (33%) complete responses (CRs) and 8 (14%) partial responses. CRs occurred more frequently in patients who had received fewer prior treatment regimens. The 1-, 2-, and 3-year overall survival (OS) rates from initiation of BV were 78%, 62%, and 41%, respectively. Conclusion: Response rates and OS in this analysis of BV in real-world settings in the Czech Republic and Slovakia were consistent with those reported for pivotal clinical trials and from previous studies outside the clinical trial setting. The results support the efficacy of BV for treatment of R/R HL in real-life clinical practice.
ER  -

KRÁL, Zdeněk; Jozef MICHALKA; Heidi MOCIKOVA; Jana MARKOVA; Alice SYKOROVA; David BELADA; Alexandra JUNGOVA; Samuel VOKURKA; Marie LUKASOVA; Vit PROCHAZKA; Juraj DURAS; Roman HAJEK; Ladislav DUŠEK; L'ubos DRGONA; Miriam LADICKA; Veronika BALLOVA a Andrei VRANOVSKY. Treatment of Relapsed/Refractory Hodgkin Lymphoma: Real-World Data from the Czech Republic and Slovakia. \textit{Journal of Cancer}. Australia: IVYSPRING INT PUBL, 2019, roč.~10, č.~21, s.~5041-5048. ISSN~1837-9664. Dostupné z: https://doi.org/10.7150/jca.29308.

Přehled o publikaci